Group 1: Industry Trends - The CXO industry in China is experiencing a recovery driven by increased demand for outsourced research and production services, with significant growth expected in 2026-2027[5] - The global CXO market is projected to grow from $197 billion in 2024 to $298 billion by 2030, representing a compound annual growth rate (CAGR) of 7%[10] - The trend of Chinese innovative drugs going global is expected to create long-term opportunities for CXO companies, enhancing their order and pricing power[16] Group 2: Investment Recommendations - BOCOM International recommends focusing on high-quality, cost-effective leaders in the CXO sector, specifically WuXi AppTec, Kelun Pharmaceutical, and Kanglongda, all rated as "Buy"[24] - WuXi AppTec is highlighted for its strong order performance and expected revenue growth, with a target price of HKD 91, indicating a potential upside of over 60%[25] - Kelun Pharmaceutical is expected to see a revenue CAGR of 16% from 2025 to 2027, with a target price of HKD 113.8, suggesting a potential upside of over 50%[25] Group 3: Key Drivers of Growth - The expansion of demand for innovative drug development and production outsourcing is a key driver for the CXO industry, with significant increases in R&D investments expected[9] - The integration of AI in drug development is anticipated to reach a critical development point in 2026, enhancing decision-making in early-stage research[9] - The industry is witnessing a trend of consolidation, where leading companies are acquiring smaller firms to enhance their technological capabilities and market presence[14] Group 4: Risks and Challenges - Potential risks include mismatches in supply and demand, particularly in new molecular types and regulatory challenges in overseas markets[5] - The increasing complexity of global supply chains and regulatory requirements may pose challenges for CXO companies lacking international experience[21] - The industry faces uncertainties related to drug pricing reforms and geopolitical factors that could impact operational stability[12]

Group 1 - The global biotech and pharmaceutical investment and financing activities are expected to rebound significantly in 2025, driven by the robust development of innovative drug technology platforms, leading to a comprehensive recovery in the CXO industry and sustained industry prosperity into 2026 [1] - The Chinese CRO market is projected to return to a growth trajectory in 2025, with a notable 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic innovative drug market [1] - The demand side globally is showing a strong rebound, establishing a solid foundation for growth, with biotech financing reaching a historical high in Q4 2025 and multinational pharmaceutical companies experiencing a recovery in demand [1] Group 2 - WuXi AppTec (药明康德) is expected to report impressive performance in 2025, with adjusted net profit increasing by 41.3%, driven by the TIDES business, which has seen revenue growth exceeding 90% [2] - WuXi Biologics has reached a record high of 945 projects, with a 30% growth in dual monoclonal and ADC projects, indicating a strong pipeline for future commercialization [2] - WuXi AppTec's subsidiary, WuXi STA, is focusing on the ADC/XDC sector, with revenue growth exceeding 40% in 2025 and an increase in global market share to over 24% [2] Group 3 - The Chinese clinical CRO market is at a clear turning point, with Tigermed (泰格医药) benefiting from the industry recovery, as order prices stabilize and the domestic clinical pipeline grows alongside improved financing conditions [3] Group 4 - Global CDMO giants are accelerating expansion, with optimistic performance guidance; Fujifilm is expected to secure $8 billion in new orders in 2025, reflecting strong demand for large molecule CDMO services [4] - Charles River anticipates an improvement in order trends starting in H2 2025, with a forecast for revenue growth in its safety assessment business by H2 2026, serving as an early indicator of recovery in the CXO industry [4] Group 5 - Investment recommendations include focusing on leading clinical CRO platforms like Tigermed and niche leaders such as Pruis, as well as front-end CRO companies with shorter order fulfillment cycles and greater marginal elasticity [5] - In the CDMO sector, attention is advised on leading companies in the peptide supply chain, ADC beneficiaries, and those with forward-looking layouts in small nucleic acids, as well as companies with significant potential for marginal traction from large products [5]